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BCG protects against
tuberculosis irrespective of
HIV status: a matched
case-control study in
Mwanza, Tanzania
While BCG vaccine protects against severe
tuberculosis (TB) in children, its effect against
adult TB is questionable. Furthermore, it is not
known if HIV co-infection modiﬁes the effect
of BCG. Among 352 pairs of Tanzanian TB
cases and matched controls, the BCG scar was
associated with a reduced risk of TB (OR 0.3,
95% CI 0.2 to 0.7, p=0.005), irrespective of
HIV status (interaction, p=0.623). BCG
vaccination considerably reduced the risk of
TB, both among individuals with and without
HIV infection.
BCG vaccination is used in most tubercu-
losis (TB)-endemic countries, and from
1980 to 2008, the coverage of BCG vac-
cination in Africa increased from 11% to
84%.1 However, the data on protection
from childhood vaccine against adult TB
are inconsistent,2 and its role in HIV
infection is unclear.3 We conducted an
age- and sex-matched case-control study
in Tanzania, to assess the protective effect
of BCG vaccination and other risk factors
for pulmonary TB.
Data were available for 352 pairs of TB
patients and non-TB controls (n=704). A
majority of cases lived alone and worked
as farmers or ﬁshermen (see online
supplementary table). Fewer cases than
controls had a visible BCG scar (78.9 vs
93.1%, p<0.001, χ2), but more cases
were HIV co-infected (46.3 vs 9.9%,
p<0.001, χ2). The associations between
TB and BCG, HIV, smoking and alcohol
intake were assessed in a multivariable
conditional logistic regression model
adjusted for age, diabetes status and socio-
demographic factors (table 1). A BCG scar
was associated with a considerable
reduction in risk of TB (OR 0.3, 95% CI
0.2 to 0.7, p=0.005), and this association
was not confounded or modiﬁed by any
of the other covariates (ie, BCG-HIV
interaction test, p=0.623). In stratiﬁed
analysis by HIV status and adjusted for
age, diabetes and sociodemographic
factors, the BCG scar was associated with
TB among both HIV-negative (0.3,
0.1;0.5, p<0.001) and HIV-positive (0.1,
0.02;0.95, p=0.045) participants. There
was a similar effect across all age groups
(data not shown), indicating a long-term
BCG effect.
The BCG efﬁcacy in 14 prospective
trials and 12 case-control studies was
50%, ranging from a zero effect to 80%,4
and a recent case-control study from India
among 412 pairs of cases and controls
reported a protective effect of BCG vac-
cination (OR 0.47, 95% CI 0.35 to
0.63).5 The variations in the observed
protective efﬁcacy have been explained as
potential differences in the BCG vaccine
strains used, the application methods, pre-
existing immunity induced by environ-
mental non-tuberculous mycobacteria, or
latent TB infection. Our study was not a
vaccine efﬁcacy study, but aimed to
examine the association between the pres-
ence of a BCG scar and developing active
TB disease, but the OR of 0.3 does reﬂect
a high efﬁcacy. Since not all
BCG-vaccinated individuals develop a
BCG scar, the presence of a BCG scar,
rather than information on BCG vaccin-
ation, might better predict protection,
since this indicates that an immunological
reaction has actually taken place.
This is the ﬁrst study providing evi-
dence strongly suggesting that BCG vac-
cination may prevent TB among both
HIV-infected and uninfected participants.
We do not have data on the time of HIV
infection in the current population, but
due to the inclusion criteria (age
>15 years), and since most patients were
antiretroviral-treatment naïve, the major-
ity of the HIV infected must have con-
tracted the infection in adulthood.
In conclusion, BCG vaccination seems
to have an overall protective effect on the
risk of developing active TB, and import-
antly, the effect is similar among
HIV-uninfected and HIV-infected adults.
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Table 1 Predictors of pulmonary tuberculosis with OR and 95% CI based on 352 pulmonary tuberculosis cases and 352 controls (n=704)
Crude* Multivariable†
OR (95% CI) p OR (95% CI) p
BCG scar 0.3 (0.2 to 0.5) <0.001 0.3 (0.2 to 0.7) 0.005
HIV infection 9.0 (5.4 to 15.1) <0.001 9.6 (4.7 to 19.5) <0.001
Smoking 3.0 (1.9 to 4.8) <0.001 2.4 (1.2 to 4.8) 0.017
Alcohol 3.0 (2.1 to 4.3) <0.001 2.8 (1.6 to 5.2) 0.001
*Univariate conditional logistic regression for matched case-control groups.
†Multivariable conditional logistic regression for matched case-control groups including all covariates from table and adjusted for age, tribe, marital status, occupation, religion and
diabetes status.
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